These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
10. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245 [TBL] [Abstract][Full Text] [Related]
11. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244 [TBL] [Abstract][Full Text] [Related]
13. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Stokes SH Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314 [TBL] [Abstract][Full Text] [Related]
14. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899 [TBL] [Abstract][Full Text] [Related]
15. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E Cancer J; 2005; 11(3):234-40. PubMed ID: 16053667 [TBL] [Abstract][Full Text] [Related]
16. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198 [TBL] [Abstract][Full Text] [Related]
17. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872 [TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
19. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E Am J Clin Oncol; 2004 Dec; 27(6):611-5. PubMed ID: 15577440 [TBL] [Abstract][Full Text] [Related]
20. Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E Brachytherapy; 2002; 1(2):95-101. PubMed ID: 15062177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]